- Home
- NUW vs CERS Comparison
NUW vs CERS Comparison
Compare NUW & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- CERS
- Stock Information
- Founded
- NUW 2008
- CERS 1991
- Country
- NUW United States
- CERS United States
- Employees
- NUW N/A
- CERS N/A
- Industry
- NUW Investment Managers
- CERS EDP Services
- Sector
- NUW Finance
- CERS Technology
- Exchange
- NUW Nasdaq
- CERS Nasdaq
- Market Cap
- NUW 246.8M
- CERS 255.0M
- IPO Year
- NUW N/A
- CERS 1997
- Fundamental
- Price
- NUW $13.93
- CERS $1.33
- Analyst Decision
- NUW
- CERS Strong Buy
- Analyst Count
- NUW 0
- CERS 2
- Target Price
- NUW N/A
- CERS $3.50
- AVG Volume (30 Days)
- NUW 45.3K
- CERS 1.2M
- Earning Date
- NUW 01-01-0001
- CERS 10-29-2025
- Dividend Yield
- NUW 3.66%
- CERS N/A
- EPS Growth
- NUW N/A
- CERS N/A
- EPS
- NUW N/A
- CERS N/A
- Revenue
- NUW N/A
- CERS $192,510,000.00
- Revenue This Year
- NUW N/A
- CERS $30.03
- Revenue Next Year
- NUW N/A
- CERS $9.37
- P/E Ratio
- NUW N/A
- CERS N/A
- Revenue Growth
- NUW N/A
- CERS 13.25
- 52 Week Low
- NUW $12.45
- CERS $1.12
- 52 Week High
- NUW $14.44
- CERS $2.24
- Technical
- Relative Strength Index (RSI)
- NUW 68.05
- CERS 54.10
- Support Level
- NUW $13.66
- CERS $1.26
- Resistance Level
- NUW $13.78
- CERS $1.34
- Average True Range (ATR)
- NUW 0.09
- CERS 0.07
- MACD
- NUW 0.02
- CERS 0.01
- Stochastic Oscillator
- NUW 90.60
- CERS 62.07
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.